Theranexus and Insud Pharma group company Exeltis have crafted a license and supply agreement to commercialise TX01.
TX01 — developed by Theranexus — is a novel formulation of a compound which has already been approved to treat multiple rare neurological diseases.
Under the terms of the agreement, Exeltis will hold the exclusive rights to the marketing and distribution of TX01 across the EU, Latin America, UK and some Middle Eastern countries.
Exeltis has paid Theranexus €2m upfront for the rights to TX01, though the company is also eligible for aggregated development and commercial milestone payments
Theranexus will also receive tiered royalties on Exeltis' net sales, as the company anticipates the strong growth and market impact of TX01.
The therapeutic will be used to treat both Gaucher and Niemann-Pick type C, providing patients with rare neurological disorders with a specialised therapeutic that could improve quality of life.
Chair and CEO of Theranexus, Mathieu Charvériat, commented: “Our agreement with Exeltis marks a significant milestone in the development of Theranexus, a validation of our strategic focus on rare neurological disorders and a confirmation of the value of our assets. Exeltis’ global infrastructure and deep market knowledge make them an ideal partner to maximize the impact of our innovative formulation.”
Exeltis' CEO, Salustiano Perez, added: “We are thrilled to join forces with Theranexus and leverage our commercial capabilities to bring this much-needed therapy to patients globally. This partnership aligns with Exeltis’ mission to enhance patient care by broadening access to life-changing treatments.”
Julien Veys, Chief Business Officer at Theranexus, concluded: “We are delighted to build this alliance with the Exeltis team, addressing the needs of an underserved patient population. With an addressable market exceeding €200 million globally and a formulation tailored for a specific segment of rare disease patients, this partnership reflects our shared commitment to advancing therapeutic innovation and improving patient outcomes.